|
|
 | | | |
- close
- close
- close
- close
Marshall Edwards (MSHL) |
Benzinga
May 29
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The...
Benzinga
May 8
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced that its majority shareholder, Novogen Limited, has exercised rights to acquire $4 million of Units, subject to availability, in Marshall Edwards' ongoing rights offering following approval at a...
Benzinga
Apr 25
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that the U.S. Patent and Trademark Office has issued Patent No. 8,163,795 covering the Company's lead drug candidate ME-143 for use in treating cancer. The patent is expected to provide...
Benzinga
Apr 10
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has received approval from the U.S Food and Drug Administration (FDA) of its...
Benzinga
Mar 27
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it has received a Notice of Effectiveness from the U.S. Securities and Exchange Commission for the Company's registration statement on Form S-1 filed in connection with its previously...
StreetInsider.com
Mar 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Marshall+Edwards+%28MSHL%29+Submits+IND+to+FDA+for+ME-344%3B+Commences+4th+Cohort+ME-143+Phase+I+Dosing/7244115.html for the full story.
Benzinga
Mar 6
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food...
Benzinga
Feb 21
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering to existing stockholders to purchase up to $8 million of its common...
StreetInsider.com
Jan 3
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Marshall+Edwards+%28MSHL%29+Receives+New+Method+of+Use+Patent+for+ME-344+in+Treatment+of+Cancer/7048830.html for the full story.
Benzinga
Dec 29
Comment
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that it has reached a definitive agreement with its majority shareholder, Novogen Limited, to sell common stock in a private placement for gross proceeds of $2 million, before deducting fees...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
